source
- Biotech has a new startup model: Small team, big check and Chinese assetsA new flavor of company is shaking up how biotechs are built. Instead of launching with eye-popping early-stage science or a new platform, there's a surge of startups with small teams, large checks…Endpoints · 2mo ago↗ source
- Windward Bio gets $165M to take China-derived drug into Phase 3 asthma trialA Swiss biotech with two experimental medicines from China, plus an in-house discovery team, has brought in $165 million to advance into late-stage testing. The startup, Windward Bio, has raised a ...Endpoints · 2mo ago↗ source
- UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseasesThe buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the “next wave” of care for immunological conditions.